WPS Stock Chart & Stats
€227.40
€1.80(0.57%)
At close: 4:00 PM EST
€227.40
€1.80(0.57%)
Day’s Range― - ―
52-Week Range€191.35 - €340.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€20.30B
Enterprise Value€25.48K
Total Cash (Recent Filing)€435.80M
Total Debt (Recent Filing)€312.10M
Price to Earnings (P/E)41.7
Beta0.16
Next Earnings
Oct 22, 2026EPS Estimate
1.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)7.87
Shares Outstanding70,375,760
10 Day Avg. Volume1
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio33.99
Price to Book (P/B)6.26
Price to Sales (P/S)6.47
P/FCF Ratio42.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€352.09Price Target Upside54.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)7.59
Revenue Forecast (FY)€2.93B
Bulls Say, Bears Say
Bulls Say
Sustained High Profitability And Margin ExpansionWest’s consistently strong gross and operating margins reflect pricing power and a favorable shift toward higher‑value HVP Components and delivery devices. Durable margin expansion supports reinvestment capacity, underwriting of R&D and capex, and resilience to cyclical volume swings over the next 2–6 months.
Very Healthy, Low‑leverage Balance SheetExtremely low leverage and a large equity cushion provide financial flexibility to fund capex, M&A or buybacks while absorbing working‑capital swings from timing issues. This structural strength reduces solvency risk and preserves strategic optionality over the medium term.
Durable Demand From HVP Components And Biologics MixHigh‑value elastomer and delivery products tied to biologics and GLP‑1 therapies drive recurring, long‑lifecycle sales with high customer qualification barriers. Strong win rates and mix shift to premium products support sustainable top‑line and margin improvement beyond short cycles.
Bears Say
Modest Overall Revenue Growth NormalizationWhile 2026 shows pockets of strong organic growth, multi‑year top‑line growth has normalized from earlier peaks. Slower aggregate revenue expansion constrains leverage benefits on fixed costs and limits upside from operating‑leverage versus periods of stronger secular growth.
Weaker Free Cash Flow Conversion And Timing PressureLower FCF conversion and episodic operating cash timing (AR build from cyber recovery) reduce near‑term cash available for buybacks or faster deleveraging. Continued capex guidance and working‑capital variability could pressure liquidity and capital allocation flexibility over coming quarters.
Segment Concentration And Contract Exit Risks In West VantageDependence on a few large contracts and recent contract exits create near‑term revenue troughs and comparability headwinds. Segment concentration increases sensitivity to customer‑specific decisions, which can amplify quarter‑to‑quarter volatility despite overall durable demand in HVP businesses.
West Pharmaceutical Services News
WPS FAQ
What was West Pharmaceutical Services, Inc.’s price range in the past 12 months?
West Pharmaceutical Services, Inc. lowest stock price was €191.35 and its highest was €340.00 in the past 12 months.
What is West Pharmaceutical Services, Inc.’s market cap?
West Pharmaceutical Services, Inc.’s market cap is €20.30B.
When is West Pharmaceutical Services, Inc.’s upcoming earnings report date?
West Pharmaceutical Services, Inc.’s upcoming earnings report date is Oct 22, 2026 which is in 88 days.
How were West Pharmaceutical Services, Inc.’s earnings last quarter?
West Pharmaceutical Services, Inc. released its earnings results on Jul 23, 2026. The company reported €2.082 earnings per share for the quarter, beating the consensus estimate of €1.829 by €0.253.
Is West Pharmaceutical Services, Inc. overvalued?
According to Wall Street analysts West Pharmaceutical Services, Inc.’s price is currently Undervalued.
Does West Pharmaceutical Services, Inc. pay dividends?
West Pharmaceutical Services, Inc. does not currently pay dividends.
What is West Pharmaceutical Services, Inc.’s EPS estimate?
West Pharmaceutical Services, Inc.’s EPS estimate is 1.91.
How many shares outstanding does West Pharmaceutical Services, Inc. have?
West Pharmaceutical Services, Inc. has 70,375,760 shares outstanding.
What happened to West Pharmaceutical Services, Inc.’s price movement after its last earnings report?
West Pharmaceutical Services, Inc. reported an EPS of €2.082 in its last earnings report, beating expectations of €1.829. Following the earnings report the stock price went up 8.939%.
Which hedge fund is a major shareholder of West Pharmaceutical Services, Inc.?
Currently, no hedge funds are holding shares in DE:WPS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
West Pharmaceutical Services Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€352.09 (54.83% Upside)
€352.09 (54.83% Upside)
Blogger Sentiment
Bullish
DE:WPS Sentiment 70%
Sector Average 65%
Sector Average 65%
Insider Transactions
Sold Shares
Worth €992.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.98%
12-Months-Change
Fundamentals
Return on Equity
0.24%
Trailing 12-Months
Asset Growth
3.13%
Trailing 12-Months
Company Description
West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
WPS Company Deck
WPS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was broadly positive: the company reported a clear top‑ and bottom‑line beat, raised full‑year guidance, and demonstrated margin expansion driven by a favorable mix toward high‑value HVP Components, Biologics and Delivery Devices. Management highlighted operational resilience after a cyber incident, strong growth in Asia Pacific, and continued capital returns. Near‑term headwinds include the cyber incident's effect on West Vantage (pushing revenue into later quarters), operating cash‑flow timing pressure, inflationary costs and FX exposure, and the comparability impact from the SmartDose 3.5 divestiture. Overall, the upside from high‑value product mix, margin gains and raised guidance meaningfully outweigh the discrete and manageable lowlights.View all DE:WPS earnings summariesWPS Revenue Breakdown
81.07% Proprietary Products
18.93% Contract-Manufactured Products
0.00% Intersegment sales elimination
WPS Stock 12 Month Forecast
Average Price Target
€352.09
▲(54.83% Upside)